Novartis just lately introduced the acquisition of Mariana Oncology, an rising biotech centered on advancing a radioligand therapeutics platform, for as much as $1.75 billion in upfronts and future milestones.
The capstone of its three quick years of operations, this acquisition represents the second largest preclinical M&A deal in historical past, and the most important ever accomplished by Novartis. It additionally represents a shift in radioligand remedy deal exercise: a real platform acquisition, fairly than one centered on a late-stage asset.
Mariana’s acquisition and the extremely thrilling radioligand remedy (RLT) area has been lined extensively elsewhere (right here, right here, right here), however we thought sharing just a few of the important thing people-related themes worthwhile.
This deal reinforces the oft-cited axiom in enterprise investing that discovering and backing nice groups is essential to success, and a giant a part of that’s leveraging deep relationships throughout the ecosystem.
Let’s begin with CEO-Founder Simon Learn, who has now joined that rarefied air of serial entrepreneurs who’ve efficiently had greater than only a fortunate billion greenback singleton; Simon was the CSO at Ra Pharma, which was acquired for $2.5B by UCB Pharma again in October 2019 (right here). We had Simon on our “PeopleFlow” checklist instantly following that acquisition, and by the tip of 2019 we had been actively recruiting him. Fortuitously for Atlas, he began as an Entrepreneur-in-Residence (EIR) within the spring. The truth is, Simon was considered one of our first “digital EIRs” to start out throughout the early days of the COVID lockdown. For the preliminary six months or so, Simon labored throughout a number of Atlas corporations, together with advising Vigil, Q32, Third Harmonic, and others.
Within the fall of 2020, Simon started working carefully with my companion Kevin Bitterman and Atlas’ Jernej Godec, who spent the prior yr starting to formulate a thesis round radiopharmaceuticals, an effort termed “Mission Curie”. A essential part of this thesis had turn out to be the idea that low molecular weight ligands, reminiscent of macrocyclic peptides like these Simon had helped uncover and develop at Ra, can be a key enabler of radioligand pharmacology. Simon was fast to acknowledge the potential alternative on this area and started working to strengthen and refine the nascent technique. To help the hassle, we additionally introduced on Sandy Mong from BridgeBio to work as an EIR with Simon on the venture. The ultimate startup pitch to the partnership was in April 2021, and Mission Curie was seeded on Could 3, 2021 – propitious timing, because it was precisely 3 years to the day that Novartis closed its acquisition of the corporate.
Initially, we partnered with Dan Becker and Christine Borowski of Entry Industries (with whom we’ve performed a number of offers with) on fleshing out the plans for the seed funding, each of whom had been distinctive companions in serving to pull all of it collectively. Specifically, Christine and Jernej had been a useful duo for Simon to lean on, partially as a result of that they had beforehand labored collectively at Appletree. They had been each instrumental within the founding of the corporate and its early plans, particularly throughout the 18+ months that Curie/Mariana incubated within the Atlas workplaces from mid-2021 till February 2022.
In Atlas’ April 2021 seed funding memo, crafted with Simon and Entry, the staff spelled out a lot of the imaginative and prescient for what made Mariana successful: the essential platform enablement that might set up Mariana as a pacesetter on this rising area, in addition to the compelling goal alternative with the preliminary lead program (now known as MC-339) in small cell lung most cancers. Nice preliminary goal choice just isn’t solely essential for advancing a pipeline, but in addition for early platform growth.
Shortly after our seed funding, we additional strengthened the broader syndicate by combining forces with our associates at RA Capital, Josh Resnick and Laura Tadvalkar, who had been engaged on a NewCo with the same focus. Notably, CSO Alonso Ricardo, who was an EIR at RA Capital, had beforehand labored alongside Simon Learn at Ra Pharma. And Josh was additionally beforehand a Enterprise Associate at Atlas, and is an efficient private good friend with many people at Atlas as nicely. It was very very like bringing the band again collectively!
Bernard Lambert, CTO of Mariana, was additionally a key early rent, becoming a member of a couple of yr into the journey from Telix Pharma, a focused radiopharmaceutical participant. Bernard actually has extra years of radiopharm expertise than most likely anybody on the planet, having labored extensively within the area for twenty-four years, and was a key enabler for the expertise. Like most new tech platforms, integrating deep area expertise – together with scars and gray hair from prior studying cycles – is essential to success.
Mariana’s COO/CFO Linda Bain was the ultimate member of the senior management staff to affix, and helped scale the corporate into its $175M Sequence B increase final fall, in preparation for a possible path to an IPO. Linda got here to Mariana from Codiak Biosciences, the place she was the CFO for seven years, and helped lead their 2020 IPO. Extensively thought to be an exceptionally gifted chief, we tried exhausting for a number of years to recruit Linda. Because of the concerted effort of all the Atlas staff, and specifically Andrea DiMella (our head of expertise), we had been capable of assist her land at Mariana.
One of many many recruitment actions that helped: Linda ran the Attain The Seashore relay with us in Sept 2022 and was caught in a van with me for 30+ hours. She might have stated sure to becoming a member of an Atlas startup simply to flee future time within the vans! Funnily sufficient, Simon additionally ran RTB with us, again in 2021. Operating is the brand new golf, as we prefer to say. This highlights one other axiom within the enterprise enterprise: discovering distinctive methods to construct deeper neighborhood pays dividends over the long term.
As for all rising biotechs, BD is an ever-present exercise – speaking to companions and maintaining them updated. That stated, the BD course of that culminated with this acquisition actually kicked off in earnest final fall because the story got here collectively for the Sequence B, and we had line of sight for MC-339 getting into the clinic. At our “Atlas Enterprise Retreat” in November 2023, interactions between Linda Bain and Shiva Malek, head of oncology analysis for Novartis, had been key in organising the BD dynamic in early 2024. The RLT area couldn’t have been hotter, with an unbelievable wave of M&A occurring in parallel with Mariana’s discussions: RayzeBio acquired by BMS, Level by Lilly, and extra just lately Fusion by AstraZeneca.
Whereas many events had been , Novartis stood out for its conviction round RLT (together with its present marketed portfolio of Lutathera and Pluvicto) and our confidence of their capacity to hold ahead the staff and platform into the clinic. In late January, following a name we had with Novartis’ Ronny Gal and Susanne Kreutz about a number of ongoing dialogues within the portfolio, Novartis expressed their curiosity in shifting ahead with an acquisition to each Simon and Atlas. Our companions at Centerview helped finalize the deal – additional strengthening their unbelievable market share within the >$1B deal class: they’ve performed a minimum of 55 M&A offers larger than $1B since 2019, greater than the following 9 advisors mixed.
As we shut this chapter of what we hope is a for much longer Mariana Oncology story, we’d prefer to thank all the CurieTx/Mariana staff that helped information this over the previous 3-4 years – and all these within the broader ecosystem that helped with its success.
It’s all the time all about relationships and other people – and, after all, the power these interactions emit!
